Treatment of Giardiasis with Praziquantel or Mebendazole

Comparative Clinical Trial of Mebendazole, Praziquantel and Metronidazole in treatment of human Giardiasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138708131431N1

Enrollment

600

Registered

2011-10-05

Start date

2008-05-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

giardiasis. Giardiasis [lambliasis]

Interventions

Intervention 1: Group 1: single- dose of Mebendazol 200mg. Intervention 2: Group 2: Metronidazole in tablet or liquid form 20 mg/kg daily in 3 doses for 7 days. Intervention 3: Group 3: 20mg/kg Praziq

Treatment - Drugs

Group 1: single- dose of Mebendazol 200mg.

Group 2: Metronidazole in tablet or liquid form 20 mg/kg daily in 3 doses for 7 days.

Group 3: 20mg/kg Praziquantle as single dose.

Eligibility

Sex/Gender

All

Age

2 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with gastrointestinal complaints including diarrhea; weight loss; anorexia or fatigue and positive for Giardaisis. Exclusion criteria: Drug side effects; Immune deficiency; consumption of current antibiotic.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Treatment of giardiasis. Timepoint: 7-10 dayes after treatment. Method of measurement: stool examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Imani

Shahrekord university of medical sciences

rastabi669@gmail.com+98 38 1333 0062

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026